Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling

References

• Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J (2013). 2020;103(3):38–40.
   PubMedGoogle Scholar
• Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5(3). doi:10.3390/jcm5030033
   PubMed Web of Science ®Google Scholar
• Yi M, Li A, Zhou L, et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72. doi:10.1186/s13045-020-00908-z
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41. doi:10.1038/s41408-021-00425-3
   PubMed Web of Science ®Google Scholar
• Strickland SA, Vey N. Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol. 2022;171:103607. doi:10.1016/j.critrevonc.2022.103607
   PubMed Web of Science ®Google Scholar
• Smallwood K, Harper A, Blackwood L. Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma. J Feline Med Surg. 2021;23(8):722–729. doi:10.1177/1098612X20972066
   PubMed Web of Science ®Google Scholar
• Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program. 2009: 396–405. doi:10.1182/asheducation-2009.1.396
   PubMedGoogle Scholar
• Short NJ, Konopleva M, Kadia TM, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506–525. doi:10.1158/2159-8290.CD-19-1011
   PubMed Web of Science ®Google Scholar
• Ma N, Zhang Z, Liao F, et al. The birth of artemisinin. Pharmacol Ther. 2020;216:107658. doi:10.1016/j.pharmthera.2020.107686
   PubMed Web of Science ®Google Scholar
• Kiani BH, Kayani WK, Khayam AU, et al. Artemisinin and its derivatives: a promising cancer therapy. Mol Biol Rep. 2020;47(8):6321–6336. doi:10.1007/s11033-020-05669-z
   PubMed Web of Science ®Google Scholar
• Efferth T. From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol. 2017;46:65–83. doi:10.1016/j.semcancer.2017.02.009
   PubMed Web of Science ®Google Scholar
• Zhao F, Vakhrusheva O, Markowitsch SD, et al. Artesunate impairs growth in cisplatin-resistant bladder cancer cells by cell cycle arrest, apoptosis and autophagy induction. Cells. 2020;9(12). doi:10.3390/cells9122643
   Web of Science ®Google Scholar
• Jiang F, Zhou JY, Zhang D, et al. Artesunate induces apoptosis and autophagy in HCT116 colon cancer cells, and autophagy inhibition enhances the artesunate-induced apoptosis. Int J Mol Med. 2018;42(3):1295–1304.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu L, Chen Y, et al. Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate. Pathol Res Pract. 2018;214(9):1467–1473. doi:10.1016/j.prp.2018.08.001
   PubMed Web of Science ®Google Scholar
• Li Y, Feng L, Li Y, et al. Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide. Leuk Lymphoma. 2014;55(6):1366–1372. doi:10.3109/10428194.2013.829573
   PubMed Web of Science ®Google Scholar
• Feng Z, Chen Q. Raised CD40L expression attenuates drug resistance in Adriamycin-resistant THP-1 cells. Exp Ther Med. 2020;19(3):2188–2194.
   PubMed Web of Science ®Google Scholar
• Teng Y, Ross JL, Cowell JK. The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. Jakstat. 2014;3(1):e28086.
   PubMedGoogle Scholar
• Wang Y, Lu HL, Liu YD, et al. Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway. Biomed Pharmacother. 2017;95:1388–1396. doi:10.1016/j.biopha.2017.09.062
   PubMed Web of Science ®Google Scholar
• Gritsina G, Xiao F, O'Brien SW, et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth. Mol Cancer Ther. 2015;14(4):1035–1047. doi:10.1158/1535-7163.MCT-14-0800
   PubMed Web of Science ®Google Scholar
• Tao Y, Li W, Yang J, et al. Exploring underlying mechanism of artesunate in treatment of acute myeloid leukemia using network pharmacology and molecular docking. Clin Transl Oncol. 2023;25(8):2427–2437. doi:10.1007/s12094-023-03125-5
   PubMed Web of Science ®Google Scholar
• Stubbins RJ, Francis A, Kuchenbauer F, et al. Management of acute myeloid leukemia: a review for general practitioners in oncology. Curr Oncol. 2022;29(9):6245–6259. doi:10.3390/curroncol29090491
   PubMed Web of Science ®Google Scholar
• McNeer NA, Philip J, Geiger H, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019;33(8):1934–1943. doi:10.1038/s41375-019-0402-3
   PubMed Web of Science ®Google Scholar
• Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–627. doi:10.1146/annurev.med.53.082901.103929
   PubMed Web of Science ®Google Scholar
• Chang YC, Lo WJ, Huang YT, et al. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin. Leuk Lymphoma. 2017;58(9):1–12. doi:10.1080/10428194.2017.1280604
   PubMed Web of Science ®Google Scholar
• Chhikara BS, Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin Drug Delivery. 2010;7(12):1399–1414. doi:10.1517/17425247.2010.527330
   PubMed Web of Science ®Google Scholar
• Shi Q, Xia F, Wang Q, et al. Discovery and repurposing of artemisinin. Front Med. 2022;16(1):1–9. doi:10.1007/s11684-021-0898-6
   PubMed Web of Science ®Google Scholar
• Huang Z, Gan S, Zhuang X, et al. Artesunate inhibits the cell growth in colorectal cancer by promoting ROS-dependent cell senescence and autophagy. Cells. 2022;11(16):2472. doi: 10.3390/cells11162472
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yi H, Yao H, et al. Artemisinin derivatives inhibit non-small cell lung cancer cells through induction of ROS-dependent apoptosis/ferroptosis. J Cancer. 2021;12(13):4075–4085. doi:10.7150/jca.57054
   PubMed Web of Science ®Google Scholar
• Drenberg CD, Buaboonnam J, Orwick SJ, et al. Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother Pharmacol. 2016;77(6):1231–1243. doi:10.1007/s00280-016-3038-2
   PubMed Web of Science ®Google Scholar
• Cao D, Chen D, Xia JN, et al. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation. Biomed Pharmacother. 2022;155:113705. doi:10.1016/j.biopha.2022.113705
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y, Yin C, et al. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis. Cell Death Dis. 2022;13(4):379. doi:10.1038/s41419-022-04810-z
   PubMed Web of Science ®Google Scholar
• Agashe RP, Lippman SM, Kurzrock R. JAK: not just another kinase. Mol Cancer Ther. 2022;21(12):1757–1764. doi:10.1158/1535-7163.MCT-22-0323
   PubMed Web of Science ®Google Scholar
• Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–248. doi:10.1038/nrclinonc.2018.8
   PubMed Web of Science ®Google Scholar
• Moser B, Edtmayer S, Witalisz-Siepracka A, et al. The ups and downs of STAT inhibition in acute myeloid leukemia. Biomedicines. 2021;9(8). doi:10.3390/biomedicines9081051
   Web of Science ®Google Scholar
• Almajali B, Johan MF, Al-Wajeeh AS, et al. Gene expression profiling and protein analysis reveal suppression of the C-Myc oncogene and inhibition JAK/STAT and PI3 K/AKT/mTOR signaling by thymoquinone in acute myeloid leukemia cells. Pharmaceuticals (Basel). 2022;15(3):307. doi: 10.3390/ph15030307
   PubMedGoogle Scholar
• Sha C, Jia G, Jingjing Z, et al. miR-486 is involved in the pathogenesis of acute myeloid leukemia by regulating JAK-STAT signaling. Naunyn-Schmiedeberg's Arch Pharmacol. 2021;394(1):177–187. doi:10.1007/s00210-020-01892-4
   Google Scholar
• Wang L, Zhang H, Lei D. microRNA-146a promotes growth of acute leukemia cells by downregulating ciliary neurotrophic factor receptor and activating JAK2/STAT3 signaling. Yonsei Med J. 2019;60(10):924–934. doi:10.3349/ymj.2019.60.11.1093
   PubMed Web of Science ®Google Scholar
• Shen M, Xu Z, Xu W, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. 2019;38(1):149. doi:10.1186/s13046-019-1161-8
   PubMedGoogle Scholar
• Ham IH, Wang L, Lee D, et al. Curcumin inhibits the cancer-associated fibroblast-derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway. Int J Oncol. 2022;61(1):85. doi: 10.3892/ijo.2022.5375
   PubMed Web of Science ®Google Scholar
• Sabaawy HE, Ryan BM, Khiabanian H, et al. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis. 2021;42(12):1411–1419. doi:10.1093/carcin/bgab075
   PubMed Web of Science ®Google Scholar